SCHEMBL1775832

SCHEMBL1775832

COC(=O)c1ccccc1-c1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 5/20 0.74
SLC6A4 P31645 3/20 0.74
SLC6A2 P23975 1/20 0.65
LMNA P02545 1/20 0.57
TSHR P16473 1/20 0.57
BCAT2 O15382 1/20 0.57
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
POLB P06746 2/20 0.55
GAA P10253 1/20 0.55
ALDH1A1 P00352 1/20 0.55
CFTR P13569 1/20 0.55
HSD17B10 Q99714 1/20 0.55
PDCD1 Q15116 1/20 0.55
CD274 Q9NZQ7 1/20 0.55
CHRNB2 P17787 1/20 0.55
CHRNB4 P30926 1/20 0.55
CHRNA3 P32297 1/20 0.55
CHRNA4 P43681 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL27467504 0.98 SLC6A3 (0.72) SLC6A3SLC6A4SLC6A2LMNATSHR
Phosphine SCHEMBL11469830 0.98 SLC6A3 (0.72) SLC6A3SLC6A4SLC6A2LMNATSHR
SCHEMBL31318316 0.96 SLC6A3 (0.78) SLC6A3SLC6A4SLC6A2LMNATSHR
SCHEMBL27843639 0.96 SLC6A3 (0.74) SLC6A3SLC6A4SLC6A2LMNATSHR
Boric Acid SCHEMBL28688633 0.94 SLC6A3 (0.68) SLC6A3SLC6A4SLC6A2LMNATSHR
Trimethylammonium SCHEMBL27605080 0.94 SLC6A3 (0.68) SLC6A3SLC6A4SLC6A2LMNATSHR
SCHEMBL5700615 0.94 SLC6A3 (0.72) SLC6A3SLC6A4SLC6A2LMNATSHR
SCHEMBL31109161 0.92 SLC6A3 (0.65) SLC6A3SLC6A4SLC6A2LMNATSHR
SCHEMBL22256434 0.92 SLC6A3 (0.65) SLC6A3SLC6A4SLC6A2LMNATSHR
SCHEMBL22256425 0.92 SLC6A3 (0.65) SLC6A3SLC6A4SLC6A2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114436833-B Preparation method of telmisartan key intermediate 4' -bromomethyl biphenyl-2-carboxylate 南京红太阳医药研究院有限公司 2024-12-24 CN claimed
CN-114890856-B Method for synthesizing 2,2' -biphenyl-1-carboxylic acid derivative 华南理工大学 2023-08-22 CN claimed
WO-2023088285-A1 SMALL MOLECULE INHIBITOR AGAINST NASOPHARYNGEAL CARCINOMA, PREPARATION METHOD FOR COMPOUND AND APPLICATION THEREOF 深圳湾实验室 2023-05-25 WO claimed
CN-116135850-A Preparation method and application of small molecule inhibitor and compound for resisting nasopharyngeal carcinoma 深圳湾实验室 2023-05-19 CN claimed
CN-114055791-A Method for bonding middle frame of mobile terminal and piece to be bonded 韦尔通(厦门)科技股份有限公司 2022-02-18 CN claimed
CN-108203623-B Composition, preparation method thereof and application of composition as tobacco flavor 青岛新昆仑生物科技有限公司 2021-04-27 CN claimed
CN-109553704-B Catalyst component for olefin polymerization, catalyst and application 中国石油化工股份有限公司 2021-04-13 CN claimed
CN-109553703-B Catalyst component for olefin polymerization and preparation method thereof 中国石油化工股份有限公司 2021-04-13 CN claimed
CN-109553711-B Catalyst component for olefin polymerization and catalyst thereof 中国石油化工股份有限公司 2021-04-13 CN claimed
CN-109553706-B Catalyst component for olefin polymerization, catalyst and application 中国石油化工股份有限公司 2021-04-13 CN claimed
CN-101712648-B Synthesis method of azepine anthraquinone NANJING UNIVERSITY OF TECHNOLOGY 2011-11-09 CN claimed
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US claimed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US claimed
EP-1805146-A4 PROCESS FOR PREPARING TELMISARTAN REDDYS LAB LTD DR (IN) 2009-01-14 EP claimed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US claimed
US-20070287840-A1 Process for Preparing Telmisartan DR. REDDY'S LABORATORIES LIMITED (IN) 2007-12-13 US claimed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 EP claimed
EP-1805146-A2 PROCESS FOR PREPARING TELMISARTAN Dr. Reddy's Laboratories Ltd. (IN) 2007-07-11 EP claimed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO claimed
WO-2006044754-A2 PROCESS FOR PREPARING TELMISARTAN DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-27 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 SLC6A3 413/4885SLC6A4 886/4885SLC6A2 775/4885
US-20070287840-A1 Process for Preparing Telmisartan AGT, TTR, REN SLC6A3 3387/4885SLC6A4 1416/4885SLC6A2 2289/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 SLC6A3 363/4885SLC6A4 844/4885SLC6A2 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.